移植物抗白血病效应对急性淋巴细胞白血病生存的影响
该研究基于国际血液与骨髓移植研究中心登记的5215例急性淋巴细胞白血病移植受者,分析移植物抗宿主病(GVHD)与移植物抗白血病(GVL)效应的关系。结果显示,GVHD与更强的GVL效应相关;仅低级别急性GVHD在首次或第二次完全缓解(CR1/CR2)患者中、或慢性GVHD在晚期患者中,对总生存产生净获益。
要点
- CR1/CR2患者发生急性或慢性GVHD与较低复发风险相关(HR 0.49-0.69)。
- CR1/CR2患者I-II级急性GVHD且无慢性GVHD者总生存最佳(HR 0.83-0.76)。
- III-IV级急性GVHD增加非复发死亡(HR 2.69-3.91),抵消复发保护,总生存更差。
核心结论
- GVHD与急性淋巴细胞白血病中增强的GVL效应相关。
- 仅当GVL效应与CR1/CR2患者的低级别急性GVHD相关,或与晚期患者的慢性GVHD相关时,才对总生存产生净获益。
研究设计与样本
- 回顾性队列研究,纳入国际血液与骨髓移植研究中心登记的5215例接受异基因造血细胞移植的急性淋巴细胞白血病患者。
- 分为3个队列:2593例成人CR1/CR2、1619例儿童CR1/CR2、1003例晚期(CR≥3或活动性疾病)患者。
主要发现
- CR1/CR2患者发生急性GVHD或慢性GVHD较无GVHD者复发风险更低(HR 0.49-0.69)。
- 晚期患者发生III-IV级急性GVHD或慢性GVHD者复发风险也更低(HR 0.52-0.67)。
- CR1/CR2成人及儿童中,I-II级急性GVHD且无慢性GVHD者较无GVHD者总生存最佳(死亡风险降低,HR 0.83-0.76)。
- 全部3个队列中,III-IV级急性GVHD伴随非复发死亡增加(HR 2.69-3.91),抵消复发保护,导致总生存更差。
- 晚期患者发生慢性GVHD伴或不伴I-II级急性GVHD时总生存更好(死亡风险降低,HR 0.69-0.73)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as a function of graft-versus-host disease (GVHD) offers the potential to improve survival. We examined 5215 transplant recipients with ALL reported to the Center for International Blood and Marrow Transplant Research registry. Overall survival (OS) was compared according to the presence and severity of GVHD and evaluated in 3 cohorts: 2593 adults in first or second complete remission (CR1/CR2), 1619 pediatric patients in CR1/CR2, and 1003 patients with advanced (CR ≥3 or active disease) ALL. For patients in CR1/CR2, development of acute GVHD (aGVHD) or chronic GVHD (cGVHD) was associated with lower risk of relapse than no GVHD (hazard ratio [HR], 0.49-0.69). Patients with advanced ALL developing grades III and IV aGVHD or cGVHD were also at lower risk of relapse (HRs varied from 0.52 to 0.67). Importantly, adult and children in CR1/CR2 with grades I and II aGVHD without cGVHD experienced the best OS compared with no GVHD (reduction of mortality with HR, 0.83-0.76). Increased nonrelapse mortality accompanied grades III and IV aGVHD (HRs varied from 2.69 to 3.91) in all 3 cohorts and abrogated any protection from relapse, resulting in inferior OS. Patients with advanced ALL had better OS (reduction in mortality; HR, 0.69-0.73) when they developed cGVHD with or without grades I and II aGVHD. In conclusion, GVHD was associated with an increased GVL effect in ALL. GVL exerted a net beneficial effect on OS only if associated with low-grade aGVHD in CR1/CR2 or with cGVHD in advanced ALL.
引用
- Yeshurun M, Weisdorf D, Rowe JM, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019. PMID: 30808685. doi:10.1182/bloodadvances.2018027003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。